Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRX Pharmaceuticals Inc (NRXP) provides investors and healthcare professionals with critical updates on novel therapies for central nervous system disorders and pulmonary diseases. This page aggregates official press releases, clinical trial developments, and regulatory milestones related to the company’s NMDA platform and ketamine-based treatments.
Visitors gain access to verified information about NRX-100 and NRX-101 – investigational therapies targeting suicidal depression and bipolar disorder – along with strategic initiatives through subsidiary HOPE Therapeutics. The resource prioritizes clarity in explaining complex biopharmaceutical concepts while maintaining scientific precision.
Key content includes updates on Fast Track designations, New Drug Application progress, and innovations in preservative-free drug formulations. The curated news collection serves as a decision-making tool for tracking the company’s progress in addressing unmet medical needs through rigorous clinical research.
Bookmark this page for streamlined access to NRX Pharmaceuticals’ latest developments in interventional psychiatry and small-molecule therapeutics. Check regularly for authoritative updates on pipeline advancements and regulatory strategy execution.
NRx Pharmaceuticals (NASDAQ: NRXP) has announced that its CEO, Jonathan Javitt, will present updates on the company’s business during the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 1:30 PM EST. The presentation can be accessed through a provided link. NRx is known for its investigational product ZYESAMI®, aimed at treating COVID-19 and currently in phase 3 trials supported by various US government bodies. The company is also advancing NRX-101 for treating suicidal bipolar depression, with readouts expected in 2022.
NRx Pharmaceuticals (NRXP) announced a significant FDA review outcome allowing high-volume production of ZYESAMI® (aviptadil). The FDA confirmed no clinical hold on manufacturing, enabling the drug to be produced under Good Manufacturing Practices (GMP) at scales of 10,000 to 100,000 doses. Additionally, the shelf life of ZYESAMI has been extended from 62 to 150 days. This development paves the way for NRx to potentially explore ZYESAMI's application in various severe lung injury conditions beyond COVID-19.
NRx Pharmaceuticals (NRXP) plans to announce its third-quarter 2021 financial results on November 16, 2021, before market opening. A conference call and webcast will follow at 8:30 AM ET to discuss these results and provide updates on clinical and corporate developments. Investors wishing to participate can submit questions via email in advance. The call will also be accessible through a toll-free number and a dedicated webcast link. NRx is focused on significant projects, including ZYESAMI® for COVID-19 and NRX-101 for bipolar depression.
NRx Pharmaceuticals (NASDAQ: NRXP) has completed a business mission to Luxembourg, securing a business license and establishing banking relations with BNP Paribas. The initiative focuses on setting up vaccine manufacturing capabilities for the BriLife vaccine, aiming for a production capacity of over 300 million doses annually. The company has contracted with a local firm for tech transfer and scale-up processes, in line with Good Manufacturing Practices. NRx intends to advance the BriLife vaccine in response to COVID-19 variants, with plans to finalize its vaccine development program before the holiday season.
NRx Pharmaceuticals (NASDAQ: NRXP) announced on Nov. 4, 2021, that the FDA declined to grant Emergency Use Authorization (EUA) for its COVID-19 treatment, ZYESAMI (aviptadil). The FDA cited insufficient data regarding the drug's benefits and risks in critically ill patients. NRx plans to submit data from additional patients treated in the NIH ACTIV-3b trial for FDA review. The ongoing trial has enrolled over 300 patients and reported no new safety issues. NRx is pursuing regulatory approval while making ZYESAMI available under Right to Try laws.
NRx Pharmaceuticals (NASDAQ: NRXP) reported positive safety findings for ZYESAMI® (aviptadil) from the NIH-sponsored ACTIV-3b Phase 3 study, with no new safety concerns noted in over 300 patients. The Independent Data Safety Monitoring Board recommended continued enrollment, reinforcing ZYESAMI's safety for Critical COVID-19 patients lacking alternative treatments. As of now, nearly 600 patients have been treated without unexpected serious adverse events. NRx submitted a request for Emergency Use Authorization for ZYESAMI on May 31, 2021, which is still pending.
NRx Pharmaceuticals (Nasdaq: NRXP) announced peer-reviewed results highlighting the efficacy of aviptadil in treating respiratory failure in Critical COVID-19 cases. The study found a 60-day survival rate of 81% for aviptadil-treated patients, compared to 21% for standard care (P<.0001). Additional benefits included significant improvements in respiratory distress and cytokine levels. Conducted at Houston Methodist Hospital, the trial focused on high-risk patients with comorbidities who had not responded to other treatments. Aviptadil demonstrated rapid respiratory function improvements with no severe drug-related adverse events reported.
On October 12, 2021, NRx Pharmaceuticals (NRXP) announced the submission of a revised Investigational New Drug module to the FDA for ZYESAMI™ (aviptadil), confirming Nephron Pharmaceuticals' capacity for commercial-scale production. This module supports the FDA's rolling review for the New Drug Application of ZYESAMI.
Additionally, an EU QP Auditor completed a successful inspection of a separate manufacturing facility, which is a critical step for ZYESAMI's approval in the EU and UK.
NRx Pharmaceuticals (NRXP) announced a positive safety update for ZYESAMI™ (aviptadil) during its ACTIV-3b critical care study, led by the NIH. The Independent Data Safety Monitoring Board reviewed 231 patients and reported no new safety concerns, recommending continued enrollment. This follows the safety database growing to over 500 patients with no serious adverse events linked to the drug. ZYESAMI™ is being tested in hospitalized patients with acute respiratory failure due to COVID-19, alongside remdesivir. The announcement emphasizes NRx's commitment to advancing COVID-19 treatments.
NRx Pharmaceuticals (Nasdaq: NRXP) reported promising one-year results for ZYESAMI™ treatment in COVID-19 patients with high comorbidity. A trial showed a statistically significant 3-fold increase in survival rates, with 60% alive post-treatment compared to 20% on standard care. Conducted from June to September 2020, the study demonstrates ZYESAMI's potential in critical cases. These findings align with previous data showing improved survival at 60 days. ZYESAMI is currently under FDA review for Emergency Use Authorization.
